Day One Biopharmaceuticals (NasdaqGS:DAWN) received a positive opinion from the European CHMP for conditional marketing authorization of OJEMDA (tovorafenib). The recommendation covers children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results